David W Eyre Selected Research

David W Eyre Research Topics

Disease

32	Infections 04/2024 - 05/2014
15	COVID-19 02/2024 - 01/2020
5	Reinfection 02/2024 - 05/2014
4	Clostridium Infections 10/2020 - 02/2012
4	Gonorrhea 01/2020 - 01/2019
3	Cross Infection (Nosocomial Infection) 11/2021 - 04/2017
1	Human Influenza (Influenza) 04/2024
1	Pneumonia (Pneumonitis) 04/2024
1	Communicable Diseases (Infectious Diseases) 11/2023
1	Neoplasms (Cancer) 11/2023
1	Breakthrough Infections 01/2023
1	Bacterial Infections (Bacterial Infection) 01/2023
1	Urinary Tract Infections (Urinary Tract Infection) 01/2023
1	Pharyngitis (Sore Throat) 08/2022
1	Myalgia 08/2022
1	Ageusia (Hypogeusia) 08/2022
1	Dyspnea (Shortness of Breath) 08/2022
1	Headache (Headaches) 08/2022
1	Fatigue 08/2022
1	Fever (Fevers) 08/2022
1	Cough 08/2022
1	Virus Diseases (Viral Diseases) 01/2022
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022
1	Disease Progression 01/2022
1	Anosmia 02/2021
1	Intraabdominal Infections 10/2020
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2018
1	Hodgkin Disease (Hodgkin's Disease) 11/2017
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2016

Drug/Important Bio-Agent (IBA)

10	VaccinesIBA 04/2024 - 01/2019
10	Immunoglobulin G (IgG)IBA 11/2023 - 01/2020
8	Anti-Bacterial Agents (Antibiotics)IBA 04/2024 - 02/2012
6	AntibodiesIBA 11/2023 - 01/2020
6	BNT162 VaccineIBA 01/2022 - 01/2021
3	N-methyl-valyl-amiclenomycin (BA 2)IBA 02/2024 - 08/2022
3	N-(2-cyanoethylene)urea (BA 1)IBA 02/2024 - 08/2022
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 09/2018
3	Cephalosporins (Cephalosporin Antibiotics)IBA 01/2020 - 04/2017
2	SolutionsIBA 02/2024 - 01/2019
2	Vancomycin FDA LinkGeneric 11/2023 - 05/2014
2	Proteins (Proteins, Gene)FDA Link 11/2023 - 01/2022
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2020
2	COVID-19 VaccinesIBA 01/2022 - 01/2021
2	ChAdOx1 nCoV-19IBA 01/2022 - 01/2021
2	FluoroquinolonesIBA 12/2019 - 04/2017
1	Antiviral Agents (Antivirals)IBA 04/2024
1	Amoxicillin-Potassium Clavulanate Combination (Co-amoxiclav)FDA Link 04/2024
1	Amoxicillin (Wymox)FDA LinkGeneric 04/2024
1	carbapenemaseIBA 11/2023
1	Linezolid (Zyvox)FDA Link 11/2023
1	Third Generation CephalosporinsIBA 11/2023
1	Nucleocapsid ProteinsIBA 11/2023
1	AntigensIBA 01/2023
1	Infliximab (Remicade)FDA Link 01/2022
1	SARS-CoV-2 spike proteinIBA 01/2022
1	vedolizumabIBA 01/2022
1	Palivizumab FDA Link 01/2022
1	2019-nCoV Vaccine mRNA-1273IBA 01/2022
1	EpitopesIBA 01/2022
1	Immunoglobulin A (IgA)IBA 01/2022
1	eravacyclineIBA 10/2020
1	Viral RNAIBA 01/2020
1	Azithromycin (Zithromax)FDA LinkGeneric 01/2020
1	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2020
1	Immunoglobulin M (IgM)IBA 01/2020
1	Clindamycin (Cleocin)FDA LinkGeneric 12/2019
1	zoliflodacinIBA 01/2019
1	Fluconazole (Zonal)FDA LinkGeneric 10/2018
1	idelalisibIBA 01/2018
1	Brentuximab VedotinIBA 11/2017
1	pixantrone (BBR 2778)IBA 01/2016
1	NucleotidesIBA 05/2014
1	FidaxomicinIBA 05/2014
1	Biomarkers (Surrogate Marker)IBA 06/2013

Therapy/Procedure

2	Therapeutics 01/2022 - 01/2017
1	Self-Testing 01/2023
1	Treatment Delay 01/2022
1	Drug Therapy (Chemotherapy) 11/2017
1	Stem Cell Transplantation 01/2016